Topic
Biotech
242 published works
Garrigues | Intellectual Property Blog
New genomic techniques (NGT): the new European framework for plant innovation
By Garrigues
A new regulatory framework has commenced for new genomic techniques and is set to transform plant innovation in Europe. Beyond the opportunities to develop more competitive and sustainable varieties, the…
GoodLifeSci
EU Biotech Act I: Parliament and Council back Europe’s biotech competitiveness agenda – SPC incentive now the key battleground
By Josefine Sommer, Alix Vermulst, Maarten Meulenbelt, Dr. Chris Boyle
Momentum is building behind the European Biotech Act I. The European Parliament and the Council of the EU broadly back the competitiveness agenda, with strong cross-party support for faster clinical…
Arnold & Porter: News & Perspectives
Part II: Biotech Deals — Handling of Complex Licensing Disputes
Please join Arnold & Porter for Part II of our in-person series for legal and business leaders at biotechnology companies seeking to optimize their licensing and partnering strategies. In this…
HLC - All Publications
FDA signals more inspections, scrutiny of clinical trials outside the U.S.
By Cadwalader Wickersham & Taft
Michael Davis and Karim Mikhail, named last week as permanent directors of the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) and the Center for…
Global Policy Watch
The Proposed EU Biotech Act: New Biosecurity Rules for Artificial Intelligence and Biotechnology Companies
By Bart Van Vooren, Yuliya Gevrenova
The global biotechnology landscape is evolving at an unprecedented speed, driven by advances in synthetic biology and genome editing, which, coupled with AI, make biotechnology stand at the forefront of…
Spicy IP
SpicyIP Tidbit: CGPDTM Calls for Comments and Suggestions on New Draft Pharma and Biotech Patent Application Guidelines (2026)
In the time of this oncoming monsoon, it feels like its raining draft guidelines from the Controller General’s office! The office of the Controller General of Patents, Designs and Trademarks…
The Social Media Butterfly
The Business of Building: A Conversation with David H. Crean, Founder and Managing Partner of Cardiff Advisory
For this edition of the Business of Building, I spoke with David H. Crean, Ph.D., founder and managing partner of Cardiff Advisory, whose career has taken him from the research…
Big Molecule Watch
Eli Lilly to Acquire Merida Biosciences
By Emma Murray
On August 31, 2026, Eli Lilly and Merida Biosciences (“Merida’) announced that they have entered into a definitive agreement for Lilly to acquire Merida. Under the terms of the agreement,…
Inside EU Life Sciences
The Proposed EU Biotech Act: New Biosecurity Rules for Artificial Intelligence and Biotechnology Companies
By Bart Van Vooren, Yuliya Gevrenova
The global biotechnology landscape is evolving at an unprecedented speed, driven by advances in synthetic biology and genome editing, which, coupled with AI, make biotechnology stand at the forefront of…
The IPKat
Thinking beyond the sequence: CAR-T cell therapy litigation at the UPC (2seventy bio v Johnson & Johnson, UPC_CFI_029/2026)
The loss of market share we are already seeing for on-market cell therapy products is a result of in-class competitors for the same target and indication from rival innovator companies,…